Prof Kevin Park

Professor Molecular and Clinical Pharmacology

Biography

Personal Distinctions
  • 17th North American Regional ISSX Meeting (Invitation to Speak, ISSX 2011)
  • Hot Tips in Safety Sciences (Invitation to Speak, EUFEPS and SafeSciMET 2011)
  • FRAME Lecture (Invitation to Speak, University of Nottingham 2011)
  • HepaRG Workshop (Invitation to Speak, Université de Rennes 1 2011)
  • Colloquium in Toxicology (Invitation to Speak, Universitätsmedizin Berlin 2011)
  • University of Dundee (Invitation to Speak, University of Dundee 2011)
  • Malcolm Campbell Memorial Award (Malcolm Campbell Memorial Award sub-committee 2011)
  • BRI (Invitation to Speak, BRI 2010)
  • FIP PSWC/AAPS (Invitation to Speak, FIP PSWC/AAP 2010)
  • 9th International ISSX Meeting (Invitation to Speak, ISSX 2010)
  • DHM4 (Invitation to Speak, DHM4 2010)
  • Society of Toxicology Annual Meeting (Invitation to Speak, Society of Toxicology 2010)
  • Fellow of the British Toxicology Society (British Toxicology Society 2006)
  • Vane Medal (British Pharmacological Society 2006)
  • Fellow of the British Toxicological Society (British Toxicological Society 2006)
  • Fellow of the Academy of Medical Sciences (Academy of Medical Sciences 2005)
  • Fellow of the Academy of Medical Sciences (Academy of Medical Sciences 2005)
  • FIGON Medicines Days (Netherlands 2005)
  • European ISSX (Invitation to Speak, Nice 2005)
  • Gordon Conference (Invitation to Speak, USA 2005)
  • Safety Strategy Regulations (Invitation to Speak, Hamburg 2005)
  • Geneva (Invitation to Speak, January 2005)
  • Role of chemically reactive metabolites (Invitation to Speak, Drug Metabolism Discussion Group, Warwick 2005)
  • Design of safer antimalarials (Invitation to Speak, Geneva 2005)
  • The needs of preclinical drug development in 2015 (Invitation to Speak, Safety Strategy Regulations, Hamburg 2005)
  • Mechanistic aspects of idiosyncratic drug reactions (Invitation to Speak, Gordon Conference, USA 2005)
  • Reactive intermediates and proteomics (Invitation to Speak, European ISSX, Nice 2005)
  • How can we select drugs with a low potential for toxicity as early as possible (Invitation to Speak, FIGON Medicines Days, Netherlands 2005)
  • Pfizer Medal for Innovative Science (Pfizer 2001)
  • Werner Kalow Lectureship, Toronto, Canada (Werner Kalow 2000)
  • University Australasian Visitor (Australia 2000)
  • Smith Kline and Beecham Prize (Prize, British Pharmacological Society 1993)
  • Prizer Academic Award (Pfizer 1990)
  • Sandoz Prize (Prize, British Pharmacological Society 1985)
  • AMAPI Prize (Prize, Clinical Section of the British Pharmacological Society 1983)
  • Parke-Davis Prizewinner (Prize, Parke-Davis 1974)
Untitled Document